Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them.
The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Histological or cytological diagnosis of locally advanced or metastatic solid tumors known to have approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents
- Have exhausted (or refuse) all available standard of care therapy (e.g., including anti-PD1/programmed death ligand 1 [PDL1] if applicable) or for whom no standard therapy is available for their tumor type
- Patients with prior anti-PD1/PDL1 must have documentation of primary or secondary resistance to last prior anti-PD1/PDL1 therapy according to Immunotherapy Resistance Committee (SITC) (Kluger et al, 2020)
- Have at least 1 measurable lesion by RECIST 1.1 that has not been previously irradiated (for Part 2 only)
- Have recently obtained archival tumor tissue sample available, or undergo de novo tumor biopsy
- Eastern Cooperative Oncology Group (ECOG) PS 0-1
- Adequate hematologic, renal, and liver functions
- Dose Escalation (Part 1A and 1B): Any advanced or metastatic solid tumor fulfilling other relevant eligibility criteria.
- Dose Expansion (Part 2): Tumor specific cohorts (NSCLC, RCC, melanoma, MSS CRC) must have received prior approved therapies (Part 2)
Exclusion criteria
- Other active malignancy
- Recent major surgery
- Systemic anticancer therapy and chemotherapy within protocol-defined washout period
- Known or suspected hypersensitivity to prior treatment with any vaccinia oncolytic, pox virus, or antiviral agents within the past 10 years
- Current or history of myocarditis or congestive heart failure (New York Heart Association [NYHA] III-IV); unstable angina; or serious uncontrolled arrhythmia or recent myocardial infarction
- Active or history of interstitial lung disease (ILD)/pneumonitis
- Patients requiring chronic systemic immunosuppressants
- History of severe immune mediated side effect that was considered related to prior immune modulatory therapy and requiring immunosuppressive therapy
- Known symptomatic brain metastases requiring steroids
- History of or ongoing severe inflammatory skin conditions or severe eczema having required medical treatment
- Any prior or planned organ transplant
- Presence of any open, active wound requiring treatment
Trial design
Primary purpose
Allocation
Interventional model
Masking
13 participants in 5 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal